Small Cap Gainers: RAPT, ITOS, AVXL
11:40 am Tuesday, June 15th, 2021
Rapt Therapeutics Inc (NASDAQ: RAPT) jumped 115% to $39.91 and made a new high of $41.99. The company reported top-line results form its Phase 1b trial of RPT193 monotherapy in atopic dermatitis; improvements were demonstrated in all key exploratory efficacy endpoints, and RPT193 was well-tolerated, with no serious adverse events. The difference between RPT193 and placebo on percent change in EASI score and EASI-50 was statistically significant at Day 43. Co plans to advance the candidate into a Phase 2b clinical trial in atopic dermatitis. At 52-week highs.
iTeos Therapeutics Inc (NASDAQ: ITOS) surged 36% to $27.29 after the company entered into a development and commercialization collaboration with GlaxoSmithKline (GSK) for immuno-oncology candidate EOS-448. Co will receive a $625 mln upfront payment through the collaboration in addition to up to $1.45 bln in potential milestones plus royalties.
Anavex Life Sciences Corp (NASDAQ: AVXL) gained 29.61% to $20.07 after the company announced that ANAVEX 2-73 and ANAVEX 3-71 are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets highlighting the role of sigma-1 receptor activation in Alzheimer’s disease treatment.
